Open Orphan PLC #ORPH – NEJM Opinion Piece July 22, 2021 – Posted in: Open Orphan (ORPH)

The New England Journal of Medicine (NEJM) publishes editorial relating to Human Challenge Programme Open Orphan (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that an editorial opinion piece regarding the UK Government’s Human Challenge Programme has been published in the latest edition of the New England Journal of Medicine (NEJM). The piece, titled ‘Establishing the Model during an Evolving Pandemic’, explores the extensive…

Open Orphan (ORPH) Demerger Update June 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Demerger Update Further to Open Orphan’s announcement on 14 June 2021 in relation to the distribution in specie, the boards of Open Orphan and Poolbeg Pharma are pleased to announce Poolbeg’s intention to seek admission of its shares to trading on AIM, a market of the London Stock Exchange (“Admission”). Funds raised as part of Admission will be used primarily to fund the clinical trial costs associated with the development of the Company’s POLB 001 asset as a treatment for severe influenza and to acquire and…

Open Orphan (ORPH) Investor Presentation June 2021 June 3, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (ORPH) Investor Presentation June 2021.

Open Orphan PLC #ORPH – Result of General Meeting April 29, 2021 – Posted in: Blog, Open Orphan (ORPH)

Result of General Meeting Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , announces that all resolutions proposed at the General Meeting held earlier today were duly passed. Further announcements regarding the proposed Distribution in Specie will be made in due course. For further information, please contact: Open Orphan plc www.openorphan.com Cathal Friel, Executive Chairman +353 (0)…

Open Orphan PLC #ORPH – Holding(s) in Company January 29, 2021 – Posted in: Uncategorized

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Open Orphan Plc Queen Mary BioEnterprises Innovation Centre 42 New Road London E1 2AX 1b. Please indicate if the issuer is a non-UK issuer (please mark with…

Open Orphan – Result of AGM July 22, 2020 – Posted in: Open Orphan (ORPH)

22 July 2020 Open Orphan plc (“Open Orphan” or the “Company”) Result of AGM Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce that at the Company’s Annual General Meeting held today, all resolutions put to the meeting were duly passed. For further information please contact Open Orphan plc +353 (0)1…

Open Orphan – Upcoming Investor Events July 8, 2020 – Posted in: Open Orphan (ORPH)

8th July, 2020 Open Orphan Plc (“Open Orphan” or the “Company”) Upcoming Investor Events Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is delighted to be attending and presenting at a series of investor events from the 9th to 11th July 2020. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance for all of…

Open Orphan plc – Full Year Results June 24, 2020 – Posted in: Open Orphan (ORPH)

24 June 2020 Open Orphan plc (“Open Orphan” or the “Group”) Full Year Results for the year ended 31 December 2019 Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is pleased to announce its full year results for the year ended 31 December 2019. Financial Highlights Open Orphan plc (As reported) hVIVO plc (As reported) Open…

Open Orphan presenting at Hardman & Co virtual Investor Forum on 9th July, 2020 June 17, 2020 – Posted in: Open Orphan (ORPH)

Hardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020 We are delighted to announce that Open Orphan will be presenting at our next Investor Forum on Thursday 9th July. The Investor Forum connects investors with companies looking for capital. Each company will present for 10-15 minutes, followed by an opportunity for Q&A. Open Orphan (ORPH) is a publicly traded company on the London AIM and Euronext Growth stock exchanges.…

Open Orphan – Positive Phase 1 study results published in The Lancet June 15, 2020 – Posted in: Open Orphan (ORPH)

Monday 15th June, 2020 Open Orphan plc (“Open Orphan” or the “Company”) Positive Phase I study results published in The Lancet Positive results from the Phase I study of the AGS-v vaccine developed by an Open Orphan joint venture, Imutex Limited, have been published in the peer reviewed journal The Lancet AGS-v is a first-in-class mosquito saliva, standalone, vaccine candidate designed to protect against mosquito-borne diseases carried in the saliva such as Zika, Malaria, Dengue Fever and…